0001615774-16-007524.txt : 20161004 0001615774-16-007524.hdr.sgml : 20161004 20161004183023 ACCESSION NUMBER: 0001615774-16-007524 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160909 FILED AS OF DATE: 20161004 DATE AS OF CHANGE: 20161004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 212-554-4366 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oliviero James F III CENTRAL INDEX KEY: 0001434718 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-55506 FILM NUMBER: 161920665 MAIL ADDRESS: STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC. STREET 2: 750 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 3 1 s104277_form3.xml 3 X0206 3 2016-09-09 0 0001651407 Checkpoint Therapeutics, Inc. NONE 0001434718 Oliviero James F III C/O CHECKPOINT THERAPEUTICS, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 0 1 0 0 CEO and President Common Stock (Restricted) 1000000 D The shares of restricted stock vest as follows: One-third will vest over time in installments with one-half on October 13, 2017, one-fourth on October 13, 2018 and one-fourth on October 13, 2019. One-third of the shares will vest in three equal parts based on the Company's achievement of fully-diluted Market Capitalization of $250,000,000, $500,000,000, and $750,000,000 respectively. The final third will vest in two equal installments as follows: (i) one installment will vest upon the earlier of (A) the Company's first Corporate Development Transaction or (B) the first FDA approval of a Company product or medical device, and (ii) the second installment will vest upon the earlier of (A) the Company's second Corporate Development Transaction or (B) a second FDA approval of a Company product or medical device. /s/ James F. Oliviero 2016-10-04